2018
Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV
Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 62-72. PMID: 29419568, PMCID: PMC5889316, DOI: 10.1097/qai.0000000000001642.Peer-Reviewed Original ResearchConceptsFramingham risk scoreEffect of abacavirMyocardial infarctionHazard ratioHepatitis C virus infectionType 1Type 2 myocardial infarctionCrude hazard ratioC virus infectionIncident myocardial infarctionInjection drug useHistory of AIDSUse increases riskMarginal structural modelsCohort CollaborationLow CD4Antiretroviral therapyKidney functionMI outcomesTime-dependent confoundingRisk factorsMI occurrenceVirus infectionIncrease riskRisk score
2010
Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD, Research and Design N. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases 2010, 50: 1512-1520. PMID: 20415573, PMCID: PMC2862849, DOI: 10.1086/652650.Peer-Reviewed Original ResearchConceptsMean CD4 countPercentage of patientsHIV transmission riskCD4 countHIV careFirst presentationTransmission riskCells/North American AIDS Cohort CollaborationHuman immunodeficiency virus (HIV) careHuman immunodeficiency virus (HIV) servicesHeterosexual transmission riskMedian CD4 countEarly HIV diagnosisT-lymphocyte countsHIV RNA measurementsHistory of AIDSRace/ethnicityAntiretroviral exposureCohort CollaborationHIV diagnosisLymphocyte countInitial presentationMedian ageLate presentation
2009
Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America
Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD, Research and Design N. Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases 2009, 49: 1582-1590. PMID: 19845473, PMCID: PMC2871149, DOI: 10.1086/644768.Peer-Reviewed Original ResearchConceptsPlasma HIV RNA levelsCombination antiretroviral therapyHIV RNA levelsVirologic failureRegimen failureHistory of AIDSAntiretroviral therapyTreatment failureHigher plasma HIV RNA levelsAbility of therapyRNA levelsT-cell countsTreatment-naive patientsIndependent risk factorMultivariate Cox regressionAggressive therapeutic interventionMore effective optionsModified therapyHIV infectionCox regressionRisk factorsT cellsSubsequent mortalityMortality rateClinical practice